The clinical backdrop is sobering. Ascending thoracic aortic aneurysms, marked by abnormal enlargement of the aortic lumen, affect an estimated 5.3 per 100,000 people annually and arise from progressive degeneration that weakens the arterial wall. Surgical guidelines recommend replacing the ascending aorta once its diameter exceeds 5.5 centimeters in men and 5 centimeters in women, because enlargement raises the risk of rupture or dissection. The replacement graft, typically made of Dacron, is prized for its biocompatibility and durability, but it is far stiffer and less compliant than living aortic tissue. Surgeons have long reported post-operative complications, including type-B dissection of the descending aorta, distal to the implanted graft, with the aortic isthmus — the narrow segment just beyond the origin of the left subclavian artery, where the arch meets the descending aorta — recognized as the most vulnerable site. What has remained unclear is whether the increased risk stems from altered hemodynamic loading caused by the stiff proximal graft, or simply from the fact that extending a patient’s lifespan gives more time for other regions to deteriorate.

The new study does not answer that question definitively, but it equips the field with the tool needed to try. The research team, led by Ione Ianniruberto, Davide Astori, Emiliano Votta, and Alberto Redaelli at Politecnico di Milano together with collaborators at Weill Cornell Medicine, Yale University, and elsewhere, developed a fully automated patient-specific fluid–structure interaction (FSI) pipeline. FSI simulation is the computational gold standard for capturing how flowing blood deforms a vessel wall and how, in turn, the moving wall reshapes the flow. Earlier attempts by the same group and others relied on simplified surrogate approaches that treated the aortic wall as a thin linear elastic membrane, or on fully coupled simulations that were so labor-intensive they could only be applied to a single patient. The new framework, implemented in the open-source software SimVascular, automates nearly every step, transforming what once took weeks of manual model building into a standardized, repeatable workflow.

The machinery behind the pipeline is a carefully orchestrated marriage of clinical imaging and computational mechanics. High-resolution magnetic resonance angiography provides the three-dimensional anatomy of each patient’s thoracic aorta, which is automatically segmented using an artificial-intelligence-based tool called TotalSegmentator and converted into a luminal surface model. Cine-MRI, a functional imaging modality that captures the aorta pulsing through the cardiac cycle in forty frames, supplies regional measurements of wall thickness and systole-to-diastole area change — data that encode how much the vessel expands with each heartbeat. Four-dimensional flow MRI, which measures the full velocity vector of blood throughout the aortic volume at every point in the cardiac cycle, provides the inlet velocity profiles that drive the simulations. The algorithm even corrects the raw 4D flow data for eddy-current-induced errors and aliasing artifacts, and coregisters it with the anatomy using a computed phase-contrast angiography image, ensuring that velocities land in the right place in the reconstructed geometry.

Once the imaging data are harvested, the pipeline assigns mechanical properties to the aortic wall through an approach the authors describe as “patient-informed.” Because living tissue cannot simply be pulled apart to measure its stiffness before surgery, the team built a database of more than eighty candidate stress–strain curves drawn from published equi-biaxial tensile tests of human aortic tissue, classified by patient age group and underlying etiology — whether the aneurysm is degenerative or heritable, as in Marfan and Loeys–Dietz syndromes. For each patient, the algorithm selects the literature curve that best reproduces the area change actually measured from that patient’s Cine-MRI, using the Laplace equation to estimate circumferential wall stress from pressure, radius, and thickness. The selected curves are then fitted to the incompressible, hyperelastic, anisotropic Holzapfel–Gasser–Ogden constitutive model, which mathematically describes how two families of collagen fibers embedded in the aortic wall resist stretching — a crucial refinement over earlier isotropic models that ignored the tissue’s directional architecture.

Blood itself is modeled as an incompressible Newtonian fluid with a density of 1060 kilograms per cubic meter and a viscosity of 4 centipoise, a standard and well-justified simplification for the high-shear environment of large arteries. At the aortic inlet, the measured velocity field is applied directly, with velocity forced to zero along the wall edges to satisfy the no-slip condition. At the outlets — the three supra-aortic branches and the descending aorta — the pipeline attaches lumped-parameter Windkessel models, electrical-circuit-like representations of the downstream vasculature whose resistances and compliances are automatically tuned by an optimization algorithm until the simulated systolic and diastolic pressures match the patient’s measured brachial blood pressure and the simulated descending-aortic flow matches the 4D flow MRI waveform. The surrounding tissue’s mechanical support is captured through a Robin boundary condition with an external stiffness of 10,000 pascals per millimeter.

The full simulation sequence unfolds in three stages. First, a computational fluid dynamics simulation on a rigid-wall model computes the pressure field acting on the luminal surface at mean arterial pressure. Second, a structural analysis applies that pressure to the aortic wall to estimate its prestress state — the internal tension the vessel carries even at rest, which must be known to initialize realistic FSI simulations. Third, the fully coupled FSI simulation brings fluid and solid together, initialized with the computed pressure and prestress, and runs two complete cardiac cycles with a time step of just 0.1 milliseconds. The team applied this workflow to five patients with ascending aortic aneurysms treated at New York-Presbyterian Hospital between October 2023 and May 2025, each imaged within a month before surgery and again within six months after, yielding ten patient-specific simulations that systematically compared the diseased pre-operative state against the grafted post-operative one.

The results, while preliminary in a cohort of five, are remarkably consistent — and they land precisely where clinicians worry most. After graft implantation, the simulations showed increased flow-induced wall shear stress, the frictional force that blood exerts on the endothelial lining, along with increases in the time-averaged wall shear stress (TAWSS) and in the oscillatory shear index (OSI), a measure of how chaotically the direction of wall friction reverses over the cardiac cycle. All three indices rose consistently in the aortic isthmus, the region most commonly associated with post-operative dilation. Because endothelial cells are exquisitely sensitive sensors of shear stress, sustained elevation and oscillation of these forces are known triggers of adverse biological responses, including inflammatory signaling and structural degeneration of the vessel wall. In effect, the simulations suggest that stiffening the proximal aorta may redirect hemodynamic stress onto the one segment least equipped to handle it.

The study went further than scalar indices, adding a topological analysis of the wall shear stress field that tracked so-called fixed points — locations where the surface shear pattern has critical points, akin to stagnation zones in the flow landscape. Before surgery, these fixed points clustered in the ascending aorta; after grafting, they redistributed toward the isthmus region, a migration the authors interpret as a signature of localized hemodynamic disturbance that may correlate with adverse remodeling. The statistical framework was deliberately conservative: field variables were sampled in percentile distributions across a standardized isthmus region of interest, verified for non-normality with a Shapiro–Wilk test, and compared with paired non-parametric Wilcoxon signed-rank tests, with a ninety-ninth percentile threshold used to quantify near-maximum values while ruling out numerical artifacts.

What makes the work resonate beyond the aortic community is its automation. Previous state-of-the-art FSI studies validated their frameworks on single patients precisely because model generation was too manual to scale. By contrast, this pipeline — from DICOM images to simulation-ready input files — runs end-to-end through a single Python script, opening the door to longitudinal studies that could follow large cohorts of grafted patients and correlate early hemodynamic changes with later aortic remodeling. The authors are candid that five patients constitute a preliminary cohort, and the framework still depends on literature-derived stress–strain curves rather than direct tissue measurements, but the infrastructure now exists to test the compliance-mismatch hypothesis at scale. If larger studies confirm that rigid grafts systematically elevate shear stress in the isthmus, the implication for device engineering is direct: next-generation aortic grafts should be designed with controlled compliance to soften the hemodynamic impact downstream — turning a simulation pipeline into a blueprint for the operating room.

Alpha-synuclein is a naturally occurring protein found at high levels in nerve terminals, where it is thought to participate in the regulation of synaptic vesicles—the small membrane-bound packages that carry neurotransmitters between neurons. Under healthy conditions, the protein is generally soluble and dynamically shaped. But under certain circumstances, alpha-synuclein can misfold and assemble into increasingly ordered structures. These assemblies can develop into fibrils and larger deposits known as Lewy bodies, a defining pathological feature of Parkinson’s disease and related neurodegenerative disorders. The loss of dopamine-producing neurons in the substantia nigra, a region involved in movement control, ultimately contributes to tremor, rigidity, slowness of movement and other symptoms.

The new work focuses on a particularly influential experimental model of alpha-synuclein pathology. Preformed fibrils are laboratory-generated fragments of misfolded alpha-synuclein that can be introduced into neuronal systems to initiate aggregation. Once inside cells, PFFs can act as seeds, recruiting the cell’s own soluble alpha-synuclein and encouraging it to adopt abnormal conformations. This seeded aggregation model has become an important tool for studying how pathology may begin and spread through neural circuits. It does not reproduce every feature of human Parkinson’s disease, but it allows researchers to observe the conversion of soluble protein into disease-associated assemblies under controlled conditions.

Rather than trying to block the initial formation of fibrils alone, the researchers examined whether targeted degradation of alpha-synuclein could reduce the supply of protein available for seeding. Targeted degradation is a molecular strategy in which a cellular disposal system is directed toward a selected protein. In principle, such an approach can lower the concentration of a harmful or excess protein by marking it for destruction through the cell’s own quality-control machinery. The concept is different from conventional drugs that simply occupy a protein’s active site or alter its activity. A degrader is designed to promote the physical removal of the protein, potentially producing a more sustained reduction even when only a fraction of the molecule is engaged at any one time.

According to the study’s reported conclusion, targeted removal of alpha-synuclein impeded aggregation induced by PFFs. This result is important because seeded aggregation depends on a continuing supply of soluble alpha-synuclein. When that pool is reduced, there may be fewer molecules available to attach to pathological seeds, extend fibrils or generate new aggregation-competent structures. The finding therefore supports a mechanistic link between protein abundance and the ability of PFF-triggered pathology to amplify. It also suggests that reducing alpha-synuclein may influence the process at a stage when misfolded seeds are already present, rather than only preventing the protein from misfolding in the first place.

The strategy, however, involves a delicate biological balancing act. Alpha-synuclein is not simply an unwanted waste product; it is a normal neuronal protein with proposed roles in synaptic communication and membrane dynamics. Removing too much of it, or removing it for too long, could potentially interfere with normal nerve-cell function. That makes selectivity, dose, timing and distribution central questions for future development. A useful therapeutic approach would need to reduce the pathological pool or the aggregation-prone forms of alpha-synuclein while preserving enough functional protein for healthy neuronal activity. The new findings do not by themselves resolve that challenge, but they strengthen the case for investigating degradation as a controllable way to influence the protein’s lifecycle.

The study also highlights why alpha-synuclein research has increasingly moved beyond the idea of a single, static deposit. Pathology may involve a shifting population of soluble oligomers, fibrils, membrane-associated species and larger inclusions, each with different biological properties. Some forms may be more toxic than others, while aggregates can also affect cellular transport, mitochondrial function, lysosomal clearance and immune signaling. By lowering the amount of alpha-synuclein available to participate in these transitions, targeted degradation could potentially affect several stages of the pathological cascade at once. Yet the precise molecular species most responsible for neuronal injury remain an active area of investigation, and future experiments will be needed to determine which forms are removed most efficiently.

For patients, the most important implication is that the work points toward a possible disease-modifying framework rather than an immediate treatment. Parkinson’s therapies currently focus largely on restoring dopamine signaling or managing symptoms, approaches that can improve movement but do not directly eliminate the underlying alpha-synuclein pathology. A degradation-based therapy would face formidable hurdles, including delivery into the brain, penetration of the blood-brain barrier, activity in the relevant neurons and long-term safety. Researchers will also need to establish whether blocking PFF-induced aggregation in experimental systems translates into protection of neurons, preservation of movement and slowing of disease progression in living organisms. Even so, the report provides a clear experimental signal: when the cellular supply of alpha-synuclein is deliberately reduced, a major laboratory trigger of pathological aggregation loses much of its ability to drive the process. That result places targeted protein degradation among the strategies now being pursued to confront Parkinson’s disease at its molecular source.

Subject of Research: Targeted degradation of alpha-synuclein and its effect on preformed fibril-induced aggregation in Parkinson’s disease models.

Article Title: Targeted degradation of alpha-synuclein impedes PFF-induced aggregation.

Article References: Carton, B., Gelders, G., Sathe, G. et al. “Targeted degradation of alpha-synuclein impedes PFF-induced aggregation.” npj Parkinson’s Disease (2026). https://doi.org/10.1038/s41531-026-01539-w

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01539-w

Keywords: Alpha-synuclein, Parkinson’s disease, targeted protein degradation, preformed fibrils, PFF-induced aggregation, neurodegeneration, Lewy bodies, protein misfolding.

The study, published in Nature Biomedical Engineering, describes an engineered lipid nanoparticle known as CD34/LNP^DP. The platform is designed to deliver messenger RNA and CRISPR/Cas gene-editing components specifically to cells carrying CD34, a surface marker commonly associated with human HSPCs. By coupling the nanoparticle to an anti-CD34 antibody, the researchers aimed to improve cellular targeting while avoiding the need to remove stem cells from the body for laboratory manipulation.

HSPCs reside primarily in the bone marrow and are responsible for replenishing the entire blood and immune system throughout life. Their biology makes them attractive targets for treating inherited blood disorders, but also makes them unusually difficult to engineer. Many long-term haematopoietic stem cells remain in a dormant, or quiescent, state. This limits the efficiency of approaches that depend on active cell division or high rates of cellular uptake. In addition, excessive manipulation can damage stem-cell function, reducing the ability of edited cells to repopulate the blood system.

To identify a suitable delivery vehicle, the investigators screened 15 different lipid nanoparticles for their capacity to transport reporter messenger RNA into human HSPCs. Lipid nanoparticles are microscopic assemblies of fats and related molecules that can protect nucleic acids in the bloodstream and facilitate their entry into cells. The selected formulation, LNP^DP, showed effective delivery in human HSPCs under ex vivo conditions, where cells are treated outside the body, and also demonstrated activity in vivo when directed toward CD34-positive cells.

The antibody-conjugated system was then tested with CRISPR/Cas editing cargos. In this approach, messenger RNA can encode the Cas nuclease, while a guide RNA directs the nuclease to a chosen DNA sequence. Once inside the target cell, the Cas protein creates a precise break in the genome. The cell’s own repair machinery then introduces a mutation or uses a supplied template to modify the target sequence. The researchers reported high editing efficiency in human HSPCs treated ex vivo with CD34/LNP^DP, suggesting that the formulation could support gene editing without relying on viral vectors.

The next experiments examined whether the nanoparticles could work inside living organisms. Humanized mice, which carry human blood-forming cells, received the CD34/LNP^DP system through intrafemoral administration, an approach that delivers the material directly into the marrow cavity of the thigh bone. This route places the nanoparticles close to the HSPC population and may reduce the barriers associated with systemic delivery. The treatment produced efficient editing in human HSPCs and did not cause detectable disruption of overall haematopoiesis, according to the study.

One of the first genetic targets was the erythroid-specific enhancer of BCL11A. This regulatory DNA element controls the activity of BCL11A in red blood cell precursors. BCL11A normally suppresses the production of fetal haemoglobin after birth. Disrupting its erythroid enhancer can therefore reactivate fetal haemoglobin, or HbF, a form of haemoglobin that is normally abundant before birth and can compensate for defective adult haemoglobin in disorders such as sickle cell disease and some forms of beta-thalassaemia.

In the humanized mice, editing the BCL11A enhancer within HSPCs was followed by sustained HbF reactivation in erythroid cells during long-term observation. The result is important because a durable therapeutic effect requires editing of stem cells that continue to generate blood-cell descendants over time, rather than only modifying short-lived progenitor cells. The findings indicate that CD34/LNP^DP can reach a biologically meaningful HSPC compartment and preserve the transmission of the edit through blood production.

The researchers also explored a second disease model involving a mutation in ELANE, a gene associated with severe congenital neutropaenia. Variants in ELANE can impair the development and maturation of neutrophils, leaving patients vulnerable to recurrent and potentially life-threatening infections. In humanized mice carrying an ELANE mutation, intrafemoral administration of CD34/LNP^DP directed CRISPR editing toward exon 2 of the gene. The treatment achieved robust editing in human HSPCs and partially improved the defect in neutrophil development during long-term follow-up.

Although the results do not yet establish a clinical treatment, they demonstrate a potential alternative to conventional ex vivo HSPC gene therapy. Current strategies often require patients’ stem cells to be collected, purified, edited in a specialized laboratory and reinfused after conditioning treatment. An in vivo approach could eventually simplify this process, but it must overcome major challenges, including precise tissue distribution, immune reactions, dose control, off-target editing and the need to reach enough long-term stem cells to produce a durable benefit. The study’s use of an anti-CD34 antibody provides a targeting mechanism, while the nanoparticle protects and transports the gene-editing cargo.

The work also highlights the importance of delivery technology in the development of genetic medicines. CRISPR systems are capable of rewriting disease-associated DNA, but their therapeutic value depends heavily on whether they can reach the correct cells at an effective dose while minimizing unintended exposure. By combining a selected lipid formulation with antibody-mediated recognition of CD34, the researchers created a platform that targets a clinically relevant human cell population in its native bone-marrow environment. Further studies will be needed to evaluate safety, editing precision, manufacturing requirements and performance in larger and more physiologically representative models. Even so, the findings position CD34-targeted lipid nanoparticles as a promising route toward durable in vivo engineering of the human blood-forming system.

Subject of Research: In vivo genetic engineering of human haematopoietic stem and progenitor cells using CD34-targeted lipid nanoparticles.

Article Title: Engineered lipid nanoparticles for in vivo and durable editing of haematopoietic stem cells within humanized mice

Article References: Du, J., Luo, Z., Xie, D. et al. “Engineered lipid nanoparticles for in vivo and durable editing of haematopoietic stem cells within humanized mice.” Nature Biomedical Engineering (2026). https://doi.org/10.1038/s41551-026-01765-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41551-026-01765-w

Keywords: lipid nanoparticles, haematopoietic stem cells, HSPCs, CRISPR/Cas gene editing, CD34 targeting, in vivo gene therapy, BCL11A, fetal haemoglobin, ELANE, neutropaenia, humanized mice

The researchers set out to explore the potential benefits of risk-adapted screening, which aligns screening frequency and methodology with an individual’s specific risk factors. An initial analysis suggested that a one-size-fits-all approach to CRC screening might overlook at-risk populations while leading to unnecessary procedures for those at lower risk. This observation drives home the need for a more nuanced strategy, which could optimize healthcare resources while maximizing patient outcomes.

Through a randomized controlled trial involving diverse participants, this study meticulously assessed various screening methods, including colonoscopy, fecal immunochemical testing (FIT), and multi-target stool DNA tests. Participants were segmented based on their risk factors, including family history of CRC, genetic predisposition, and lifestyle factors such as diet and exercise. This segmentation allowed for a more focused and efficient screening strategy capable of enhancing early detection rates of CRC among high-risk individuals.

One of the significant findings of the study is that risk-adapted screening can lead to earlier detection of neoplastic polyps and cancer. Early diagnosis is pivotal as it dramatically increases survival rates and can reduce the need for more aggressive treatments later on. The research highlights that by identifying high-risk individuals and applying targeted screening protocols, healthcare systems can significantly decrease CRC mortality rates.

Moreover, the study also undertook a thorough cost-effectiveness analysis. By integrating clinical effectiveness data with economic evaluations, it becomes evident that risk-adapted screening is not just clinically beneficial but also economically advantageous. The findings imply that investing in personalized screening protocols could yield substantial savings for healthcare systems burdened by the rising costs of cancer management.

The implications of this research are profound. If adopted widely, risk-adapted screening could transform the landscape of colorectal cancer prevention. It underscores a shift towards personalized medicine, where treatment and preventive strategies are tailored to individual patient profiles rather than relying on general population averages. As such methodologies gain traction, they invite a re-evaluation of current guidelines that may not fully account for individual variances in risk.

In discussing the ethical ramifications, the researchers emphasize the importance of ensuring equitable access to these tailored screening programs. There must be a concerted effort to prevent disparities in healthcare access, ensuring that risk-adapted screening reaches all demographics, especially marginalized populations who are often at heightened risk yet lack access to adequate health resources.

Moreover, the research promotes further investigation into the psychological impacts of risk-adapted screening. Understanding how individuals perceive their risk and respond to screening notifications is crucial for fostering compliance and engagement with screening programs. Mental health considerations can affect outcomes, and future studies could explore how to enhance patient communication and education regarding their specific risks.

Continued research will also be pivotal in assessing the longevity and effectiveness of risk-adapted screening over time. Subsequent studies could investigate whether these screening strategies remain effective as patient demographics evolve or as new screening technologies emerge. This aligns with the broader goal of continually fine-tuning cancer prevention strategies to match the changing landscape of public health.

The study underscores the ongoing need for collaboration between researchers, healthcare providers, and policymakers to facilitate the implementation of risk-adapted CRC screening. Effective policies that support these innovations are necessary to ensure that advancements in cancer screening translate into real-world impact, ultimately leading to reduced CRC incidence and mortality.

In summary, the work of Chen HD., Lu B., Shi JF., and their colleagues is not just a contribution to scientific literature; it is a call to action. As they advocate for the adoption of risk-adapted screening protocols, they illuminate a path forward in the fight against one of the most prevalent cancers. Their findings pave the way for a future where early detection and personalized care become the standard, ultimately saving lives while conserving economic resources.

Given the growing emphasis on precision medicine and tailored healthcare interventions, this study will likely stir discussions at various levels within the medical community and beyond. Stakeholders from all sectors must collaborate to make risk-adapted screening a standard practice, ensuring that advancements in research translate into tangible public health outcomes. The opportunity to improve cancer detection rates and patient survival through more personalized strategies, as highlighted in this innovative work, cannot be underestimated.

By embracing these developments, society moves closer to a more systematic and effective approach to colorectal cancer screening, shifting the emphasis from reactive treatment to proactive prevention. This transformative research offers a glimmer of hope in combating a formidable disease, suggesting that smarter, data-driven strategies can redefine the standard of care in oncology.

Ultimately, this study serves as a reminder of the intersection of healthcare innovation and patient-centered care. Emphasizing the need for a holistic approach to cancer prevention, it showcases how targeted screening can lead to healthier populations and a more sustainable healthcare system.

Subject of Research: Risk-Adapted Colorectal Cancer Screening

Article Title: Effectiveness and cost-effectiveness of risk-adapted colorectal cancer screening: a randomized controlled trial and modeling analysis.

Article References:

Chen, HD., Lu, B., Shi, JF. et al. Effectiveness and cost-effectiveness of risk-adapted colorectal cancer screening: a randomized controlled trial and modeling analysis.
Military Med Res 12, 82 (2025). https://doi.org/10.1186/s40779-025-00671-7

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s40779-025-00671-7

Keywords: colorectal cancer, screening, risk-adapted, effectiveness, cost-effectiveness, personalized medicine, healthcare innovation, early detection, patient-centered care.